ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 82 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2020. The put-call ratio across all filers is 1.54 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $116,386 | -11.7% | 57,333 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $131,866 | -27.5% | 57,333 | -4.4% | 0.00% | -66.7% |
| Q1 2023 | $181,800 | +30.0% | 60,000 | 0.0% | 0.00% | +50.0% |
| Q4 2022 | $139,800 | +35.7% | 60,000 | +11.2% | 0.00% | 0.0% |
| Q3 2022 | $103,000 | -29.5% | 53,940 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $146,000 | -18.4% | 53,940 | -10.1% | 0.00% | 0.0% |
| Q1 2022 | $179,000 | -23.2% | 60,000 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $233,000 | +66.4% | 60,000 | +42.3% | 0.00% | -33.3% |
| Q1 2021 | $140,000 | -61.6% | 42,171 | -59.0% | 0.00% | -50.0% |
| Q4 2020 | $365,000 | +8.0% | 102,765 | -4.8% | 0.01% | -14.3% |
| Q3 2020 | $338,000 | +72.4% | 107,912 | 0.0% | 0.01% | +40.0% |
| Q2 2020 | $196,000 | +345.5% | 107,912 | +270.8% | 0.01% | +150.0% |
| Q3 2019 | $44,000 | -27.9% | 29,104 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $61,000 | – | 29,104 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Whitefort Capital Management, LP | 11,895,477 | $24,147,818 | 12.66% |
| Two Seas Capital LP | 8,280,818 | $16,810,061 | 3.38% |
| FourWorld Capital Management LLC | 1,341,907 | $2,724,071 | 0.51% |
| Tejara Capital Ltd | 180,077 | $365,556 | 0.21% |
| Woodline Partners LP | 4,719,903 | $9,581,403 | 0.11% |
| Hudson Bay Capital Management LP | 8,299,808 | $16,848,610 | 0.07% |
| Kepos Capital LP | 155,691 | $316 | 0.06% |
| Virtus ETF Advisers LLC | 40,040 | $81,281 | 0.05% |
| Centiva Capital, LP | 1,071,705 | $2,175,561 | 0.05% |
| Kades & Cheifetz LLC | 20,000 | $40,600 | 0.03% |